<DOC>
	<DOCNO>NCT00991510</DOCNO>
	<brief_summary>The purpose study investigate much drug substance `` mycophenolate mofetil '' find blood patient kidney renal transplant treat Myfenax® CellCept® . Additionally , safety side effect two product compare . All information already available product indicate safety profile two product .</brief_summary>
	<brief_title>Comparative Bioavailability Myfenax® CellCept® Kidney Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Renal transplant recipient least 12 month posttransplantation age ≥ 18 year . Maintenance treatment mycophenolate mofetil ( combination tacrolimus without corticosteroid ) . Stable dose mycophenolate mofetil ( ≥ 500 mg twice daily ) change immunosuppressive regimen least 6 week prior start study . Stable renal graft function least 3 month . Female patient must either postmenopausal ≥ 1 year , surgically sterilize negative pregnancy test require immediately prior study entry patient must continue use effective contraception . Willingness undergo studyrelated procedure . Ability comprehend willingness sign inform consent form . History allergy mycophenolate mofetil , mycophenolic acid ingredient . Multiorgan recipient ( e.g. , kidney pancreas ) previous transplant organ kidney . Rejection within past 6 month prior start study . Severe clinically relevant coexist disease . History cancer skin cancer cure . History serious clinically relevant digestive system disease last 12 month prior start study . Known suspect hereditary deficiency hypoxanthineguaninephosphoribosyltransferase ( e.g. , LeschNyhan syndrome , KelleySeegmiller syndrome ) . Known suspect liver impairment . Clinically significant thrombocytopenia , anaemia , leukopenia , neutropenia Clinically significant laboratory and/or physical change last 2 month prior start study . Use azathioprine , cholestyramine , sevelamer , probenecid within 2 week prior first administration study medication . Change concomitant medication 6 week prior start study . Use drug , prescribe overthecounter , ( except stable concomitant medication ) within 2 week prior first administration study medication . Planned expect requirement use live attenuate vaccine study . Positive test HIV , Hepatitis B C. Clinical symptom laboratory evidence cytomegalovirus infection last 6 month . Pregnant breastfeed woman . Women childbearing potential unable unwilling practice effective contraceptive measure duration study 6 week end study . History know suspected alcohol drug abuse . Any condition patient , opinion investigator may compromise evaluation study treatment may jeopardize patient 's compliance adherence protocol requirement . Previous enrollment study participation drug investigational trial within past 6 week prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>renal transplantation</keyword>
	<keyword>mycophenolate mofetil</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>immunosuppression</keyword>
</DOC>